Berberine inhibits angiogenesis in glioblastoma xenografts by targeting the VEGFR2/ERK pathway

References

• Ausprunk DH, Folkman J. 1977. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res. 14:53–65.
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, Mclendon RE, Bigner DD, Rich JN. 2006. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66:7843–7848.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. 2000. Angiogenesis in cancer and other diseases. Nature. 407:249–257.
   PubMed Web of Science ®Google Scholar
• Eom KS, Hong JM, Youn MJ, So HS, Park R, Kim JM, Kim TY. 2008. Berberine induces G1 arrest and apoptosis in human glioblastoma T98G cells through mitochondrial/caspases pathway. Biol Pharm Bull. 31:558–562.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, Novotny W. 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 3:391–400.
   PubMed Web of Science ®Google Scholar
• Ferrara N. 2005. VEGF as a therapeutic target in cancer. Oncology. 69:11–16.
   PubMed Web of Science ®Google Scholar
• Gao JL, Shi JM, Lee SM, Zhang QW, Wang YT. 2009. Angiogenic pathway inhibition of Corydalis yanhusuo and berberine in human umbilical vein endothelial cells. Oncol Res. 17:519–526.
   PubMed Web of Science ®Google Scholar
• Hamsa TP, Kuttan G. 2012. Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators. Drug Chem Toxicol. 35:57–70.
   PubMed Web of Science ®Google Scholar
• Ho YT, Yang JS, Li TC, Lin JJ, Lin JG, Lai KC, Ma CY, Wood WG, Chung JG. 2009. Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-kappaB, u-PA and MMP-2 and -9. Cancer Lett. 279:155–162.
   PubMed Web of Science ®Google Scholar
• Jie S, Li H, Tian Y, Guo D, Zhu J, Gao S, Jiang L. 2011. Berberine inhibits angiogenic potential of HepG2 cell line through VEGF down-regulation in vitro. J Gastroenterol Hepatol. 26:179–185.
   PubMed Web of Science ®Google Scholar
• Jin P, Zhang C, Li N. 2015. Berberine exhibits antitumor effects in human ovarian cancer cells. Anti-Cancer Agents Med Chem. 15:511–516.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN. 2005. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol. 207:224–231.
   PubMed Web of Science ®Google Scholar
• Knizetova P, Ehrmann J, Hlobilkova A, Vancova I, Kalita O, Kolar Z, Bartek J. 2008. Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle (Georgetown, TX). 7:2553–2561.
   PubMed Web of Science ®Google Scholar
• Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, Sun G. 2015. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 161:69–81.
   PubMed Web of Science ®Google Scholar
• Lin S, Tsai SC, Lee CC, Wang BW, Liou JY, Shyu KG. 2004. Berberine inhibits HIF-1alpha expression via enhanced proteolysis. Mol Pharmacol. 66:612–619.
   PubMed Web of Science ®Google Scholar
• Liu Q, Xu X, Zhao M, Wei Z, Li X, Zhang X, Liu Z, Gong Y, Shao C. 2015. Berberine induces senescence of human glioblastoma cells by downregulating the EGFR-MEK-ERK signaling pathway. Mol Cancer Ther. 14:355–363.
   PubMed Web of Science ®Google Scholar
• Liu X, Ji Q, Ye N, Sui H, Zhou L, Zhu H, Fan Z, Cai J, Li Q. 2015. Berberine inhibits invasion and metastasis of colorectal cancer cells via COX-2/PGE2 mediated JAK2/STAT3 signaling pathway. PLoS One. 10:e0123478.
   PubMed Web of Science ®Google Scholar
• Ma W, Zhu M, Zhang D, Yang L, Yang T, Li X, Zhang Y. 2017. Berberine inhibits the proliferation and migration of breast cancer ZR-75-30 cells by targeting Ephrin-B2. Phytomedicine. 25:45–51.
   PubMed Web of Science ®Google Scholar
• Mavria G, Vercoulen Y, Yeo M, Paterson H, Karasarides M, Marais R, Bird D, Marshall CJ. 2006. ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell. 9:33–44.
   PubMed Web of Science ®Google Scholar
• Meeran SM, Katiyar S, Katiyar SK. 2008. Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation. Toxicol Appl Pharmacol. 229:33–43.
   PubMed Web of Science ®Google Scholar
• Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. 2006. VEGF receptor signalling – in control of vascular function. Nat Rev Mol Cell Biol. 7:359–371.
   PubMed Web of Science ®Google Scholar
• Omuro A, Deangelis LM. 2013. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 310:1842–1850.
   PubMed Web of Science ®Google Scholar
• Peng PL, Hsieh YS, Wang CJ, Hsu JL, Chou FP. 2006. Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Toxicol Appl Pharmacol. 214:8–15.
   PubMed Web of Science ®Google Scholar
• Preusser M, De RS, Wöhrer A, Erridge SC, Hegi M, Weller M, Stupp R. 2011. Current concepts and management of glioblastoma. Ann Neurol. 70:9–21.
   PubMed Web of Science ®Google Scholar
• Puputti M, Tynninen O, Sihto H, Blom T, Mäenpää H, Isola J, Paetau A, Joensuu H, Nupponen NN. 2006. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res. 4:927–934.
   PubMed Web of Science ®Google Scholar
• Stupp R, Brada M, van den Bent MJ, Tonn J-C, Pentheroudakis G. 2014. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25:iii93–iii101.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
   PubMed Web of Science ®Google Scholar
• Sun Y, Xun K, Wang YT, Chen XP. 2009. A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs. Anticancer Drugs. 20:757–769.
   PubMed Web of Science ®Google Scholar
• Wang J, Qi Q, Feng Z, Zhang X, Huang B, Chen A, Prestegarden L, Li X, Wang J. 2016. Berberine induces autophagy in glioblastoma by targeting the AMPK/mTOR/ULK1-pathway. Oncotarget. 7:66944–66958.
   PubMedGoogle Scholar
• Wilhelm SM, Carter C, Tang LYa, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. 2004. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109.
   PubMed Web of Science ®Google Scholar